» Articles » PMID: 25923252

Sphingosine-1-phosphate Metabolism: A Structural Perspective

Overview
Publisher Informa Healthcare
Date 2015 Apr 30
PMID 25923252
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Sphingolipids represent an important class of bioactive signaling lipids which have key roles in numerous cellular processes. Over the last few decades, the levels of bioactive sphingolipids and/or their metabolizing enzymes have been realized to be important factors involved in disease development and progression, most notably in cancer. Targeting sphingolipid-metabolizing enzymes in disease states has been the focus of many studies and has resulted in a number of pharmacological inhibitors, with some making it into the clinic as therapeutics. In order to better understand the regulation of sphingolipid-metabolizing enzymes as well as to develop much more potent and specific inhibitors, the field of sphingolipids has recently taken a turn toward structural biology. The last decade has seen the structural determination of a number of sphingolipid enzymes and effector proteins. In these terms, one of the most complete arms of the sphingolipid pathway is the sphingosine-1-phosphate (S1P) arm. The structures of proteins involved in the function and regulation of S1P are being used to investigate further the regulation of said proteins as well as in the design and development of inhibitors as potential therapeutics.

Citing Articles

Immunomodulatory Effects of SPHK1 and Its Interaction with TFAP2A in Yellow Drum ().

Cui Y, Luo S, Wu B, Li Q, Han F, Wang Z Int J Mol Sci. 2025; 25(24.

PMID: 39769404 PMC: 11728317. DOI: 10.3390/ijms252413641.


The functional antagonist of sphingosine-1-phosphate, FTY720, impairs gut barrier function.

Sikdar S, Mitra D, Das O, Bhaumik M, Dutta S Front Pharmacol. 2024; 15:1407228.

PMID: 39224783 PMC: 11366638. DOI: 10.3389/fphar.2024.1407228.


Targeting Sphingosine 1-Phosphate Metabolism as a Therapeutic Avenue for Prostate Cancer.

Mebarek S, Skafi N, Brizuela L Cancers (Basel). 2023; 15(10).

PMID: 37345069 PMC: 10216412. DOI: 10.3390/cancers15102732.


Endocrine Therapy-Resistant Breast Cancer Cells Are More Sensitive to Ceramide Kinase Inhibition and Elevated Ceramide Levels Than Therapy-Sensitive Breast Cancer Cells.

Pal P, Millner A, Semina S, Huggins R, Running L, Aga D Cancers (Basel). 2022; 14(10).

PMID: 35625985 PMC: 9140186. DOI: 10.3390/cancers14102380.


Ceramide Metabolism Enzymes-Therapeutic Targets against Cancer.

Gomez-Larrauri A, Das Adhikari U, Aramburu-Nunez M, Custodia A, Ouro A Medicina (Kaunas). 2021; 57(7).

PMID: 34357010 PMC: 8303233. DOI: 10.3390/medicina57070729.


References
1.
Labesse G, Douguet D, Assairi L, Gilles A . Diacylglyceride kinases, sphingosine kinases and NAD kinases: distant relatives of 6-phosphofructokinases. Trends Biochem Sci. 2002; 27(6):273-5. DOI: 10.1016/s0968-0004(02)02093-5. View

2.
Pitson S, DAndrea R, Vandeleur L, Moretti P, Xia P, Gamble J . Human sphingosine kinase: purification, molecular cloning and characterization of the native and recombinant enzymes. Biochem J. 2000; 350 Pt 2:429-41. PMC: 1221270. View

3.
Weiler S, Braendlin N, Beerli C, Bergsdorf C, Schubart A, Srinivas H . Orally active 7-substituted (4-benzylphthalazin-1-yl)-2-methylpiperazin-1-yl]nicotinonitriles as active-site inhibitors of sphingosine 1-phosphate lyase for the treatment of multiple sclerosis. J Med Chem. 2014; 57(12):5074-84. DOI: 10.1021/jm500338n. View

4.
Ago H, Oda M, Takahashi M, Tsuge H, Ochi S, Katunuma N . Structural basis of the sphingomyelin phosphodiesterase activity in neutral sphingomyelinase from Bacillus cereus. J Biol Chem. 2006; 281(23):16157-67. DOI: 10.1074/jbc.M601089200. View

5.
Lynch K . Building a better sphingosine kinase-1 inhibitor. Biochem J. 2012; 444(1):e1-2. DOI: 10.1042/BJ20120567. View